Search results
Results from the WOW.Com Content Network
In all, 96% of the warts were removed. [19] The surgery was documented by the Discovery Channel and TLC in the episode "Treeman: Search for the Cure". [citation needed] However, his warts returned and he was thought to require two surgeries per year for the rest of his life to manage the warts. [20]
Dede Koswara (1971 – January 30, 2016), also known as the "Tree Man", was an Indonesian carpenter with epidermodysplasia verruciformis (EV), a rare disease that causes the human papillomavirus (HPV) to grow uncontrollably, leading to the development of warts resembling tree bark. For most of his life, he was shunned for having an unknown disease.
10-year-old Sahana Khatun may be the first female to ever be diagnosed with 'tree-man syndrome', officially know as Epidermodysplasia Verruciformis.
It's my opinion the treeman section should be put into its own article, as he is suffering a completely different disease. The redirect of "treeman" causes search results to be returned incorrectly to this disease.Nickrz 16:50, 19 October 2010 (UTC) Sources for the claim that it is a different disease?
Cutaneous fibromas (also known as deer warts [1]) are common neoplasms occurring in wild and domestic deer of many species and are caused by host-specific viral infections. [ 2 ] [ 3 ] [ 4 ] The fibromas occur most frequently in animals under 2 years of age, with cases in older deer reported occasionally or rarely.
They are not associated with any disease or illness, nor are they infectious but rather they represent a natural occurrence on the body. Therefore, no treatment is required. People with this condition sometimes consult a dermatologist because they are worried they may have a sexually transmitted infection (especially genital warts ) or some ...
There is no known treatment for disease, which was first discovered in Colorado in the 1960s, and which impacts the nervous system of deer, elk, and moose ‘Zombie deer disease’ detected in ...
Infusions of immune globulin can reduce the frequency of bacterial infections, and G-CSF or GM-CSF therapy improves blood neutrophil counts. [5]As WHIM syndrome is a molecular disease arising from gain-of-function mutations in CXCR4, preclinical studies identified plerixafor, a specific CXCR4 antagonist, as a potential mechanism-based therapeutic for the disease. [6]